These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23052962)

  • 1. How important is HIV therapy for preventing liver fibrosis progression in HIV-HCV-coinfected individuals?
    Rockstroh JK
    Antivir Ther; 2012; 17(7):1223-5. PubMed ID: 23052962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
    Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
    Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
    Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
    Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HAART on liver histology of HIV/HCV coinfected patients.
    De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
    J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
    Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
    Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes.
    Collazos J; Cartón JA; Asensi V
    HIV Med; 2011 May; 12(5):308-15. PubMed ID: 20946441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.
    Torre D; Tambini R; Cadario F; Barbarini G; Moroni M; Basilico C
    Clin Infect Dis; 2001 Nov; 33(9):1579-85. PubMed ID: 11588701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007.
    Vellozzi C; Buchacz K; Baker R; Spradling PR; Richardson J; Moorman A; Tedaldi E; Durham M; Ward J; Brooks JT;
    J Viral Hepat; 2011 May; 18(5):316-24. PubMed ID: 20367803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
    Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
    Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.
    Bonnard P; Lescure FX; Amiel C; Guiard-Schmid JB; Callard P; Gharakhanian S; Pialoux G
    J Viral Hepat; 2007 Nov; 14(11):806-11. PubMed ID: 17927617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
    Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
    Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
    Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
    Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR3 Expression Elevated on Peripheral CD8(+) Lymphocytes from HIV/HCV Coinfected Individuals.
    Kimball P; McDougan F; Stirling R
    Viral Immunol; 2011 Dec; 24(6):441-8. PubMed ID: 22111598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.